Evidence map›Paper›PMID 23730399›Full record

ArticleJournal of analytical oncology2012

Targeting Mantle Cell Lymphoma with Anti-SYK Nanoparticles.

Ingrid Cely, Seang Yiv, Qian Yin, Anoush Shahidzadeh, Li Tang, Jianjun Cheng, Fatih M Uckun

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of analytical oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Nanopharmacology in translational hematology and oncology.International journal of nanomedicine · 2014
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Ingrid CelyDevelopmental Therapeutics Program, Children's Hospital Los Angeles, Children's Center for Cancer and Blood Diseases, Los Angeles, CA 90027 ; Department of Pediatrics and Norris Comprehensive Cancer Center, University of Southern California Keck School of Medicine, Los Angeles, CA 90027.
Seang Yiv
Qian Yin
Anoush Shahidzadeh
Li Tang
Jianjun Cheng
Fatih M Uckun
University of Illinois Urbana-Champaign · USChildren's Center · USChildren's Hospital of Los Angeles · US

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fumito Ito · 1985 to 2026
$181.4M
Developing Clinically Applicable, Cancer-Targeting Polymeric NanoconjugatesDP2OD007246 · OD · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI CHENG, JIANJUN · 2010 to 2010
$2.4M
Targeting SYK Kinase in B-Lineage ALL with CD19-Specific C-61 NanoparticlesU01CA151837 · NCI · CHILDREN'S HOSPITAL OF LOS ANGELES · PI UCKUN, FATIH M · 2010 to 2014
$2.3M
Targeting SYK Tyrosine Kinase to Overcome Radiation Resistance in ALLR01CA154471 · NCI · CHILDREN'S HOSPITAL OF LOS ANGELES · PI UCKUN, FATIH M · 2011 to 2015
$1.6M
NCI NIH HHS P30 CA014089NCI NIH HHS R01 CA154471NCI NIH HHS U01 CA151837NIH HHS DP2 OD007246
6 · The paper itself

Abstract

The pentapeptide mimic 1,4-bis(9-

Identifiers

PMID23730399
PMCPMC3668349
OpenAlexW2152716432

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.